Vertex to integrate Aurora's strengths

Published: 28-Jun-2001


Vertex Pharmaceuticals and Aurora Biosciences have signed an agreement which will unite Aurora's assay development, screening and cell biology capabilities with Vertex's integrated drug discovery expertise.

See more

You may also like

Research & Development

Med Uni Graz researchers present a new approach to targeted therapy for leukaemia

Read more
Acute myeloid leukaemia (AML) is a cancer of the haematopoietic cells that causes the uncontrolled proliferation of certain immature blood cells

Trending Articles

  1. Hansa Biopharma submits BLA to FDA for Imlifidase in desensitisation for kidney transplantation Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated immune response
  2. ten23 health QC lab to support commercial product testing for US customer following FDA approvals This pivotal regulatory milestone enables FDA-compliant release and stability testing for injectable drug products throughout the clinical and commercial phases, in addition to manufacturing the commercial product
  3. LYOVAC® ECO Mode: making pharmaceutical freeze-drying leaner and greener Following the recent announcement that GEA Lyophil has received third-party certification for the energy-saving credentials of its innovative algorithm for freeze-drying applications, Dr Kevin Robinson caught up with Senior Director of Lyophilization Technology Management, Thomas Beutler, to find out more
  4. Grifols receives US FDA approval for new fibrinogen concentrate: FESILTY (fibrinogen, human-chmt) The fibrinogen concentrate complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients
  5. Grifols gets nod from European Medicines Agency for entire value chain of Grifols Egypt The institution's certification endorses the entire plasma value chain under the highest European standards and opens the door for Egypt to, once domestic needs are met, export to other markets including Europe

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Research & Development

Med Uni Graz researchers present a new approach to targeted therapy for leukaemia

Acute myeloid leukaemia (AML) is a cancer of the haematopoietic cells that causes the uncontrolled proliferation of certain immature blood cells
Manufacturing

When science meets security: the future of small molecule outsourcing

Looking across 2025 and into 2026, chemical and pharmaceutical manufacturing is navigating a period of rapid transition, with trends emerging that will influence competitiveness for years to come
Digital

Pharma in 2025–2026: AI, China and the new era of drug development

In 2025, the pace of change throughout chemical and pharmaceutical manufacturing is accelerating, creating a complex mix of emerging opportunities and structural challenges that will define the year ahead
Research & Development

Research shows that Pepaxti is effective in high-risk myeloma

Oncopeptides announces new research demonstrating that Pepaxti (melflufen) maintains its anti-myeloma activity in patients with high-risk genetic features, including deletion 17p (del(17p)) and TP53 mutations
Research & Development

Biologics at a turning point: complexity, AI and the road to 2026

Despite rapid change, the growing complexity of biologics and the rise of AI-driven design are reinforcing the increasing need for deep scientific expertise and innovation leadership, says Campbell Bunce (CB), Chief Scientific Officer at Abzena
Distribution

Yusen Logistics Group completes acquisition of Walden Health, strengthening global healthcare logistics capabilities

Yusen Logistics Global Management is pleased to announce that Yusen Logistics (Europe) BV, an overseas subsidiary of Yusen Logistics Group, has completed the acquisition of the Walden Group subsidiaries Movianto, Eurotranspharma, Transpharma International and Walden Digital
Regulatory

Grifols receives US FDA approval for new fibrinogen concentrate: FESILTY (fibrinogen, human-chmt)

The fibrinogen concentrate complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients
Subscribe now